- Q2 2024 Biora Therapeutics Inc Earnings Call TranscriptAug 12, 2024$0.5833 (-1.35%)Earnings
- Q1 2024 Biora Therapeutics Inc Earnings Call TranscriptMay 15, 2024$0.715 (-3.10%)Earnings
- Q4 2023 Biora Therapeutics Inc Earnings Call TranscriptMar 26, 2024$1.33 (+9.02%)Earnings
- Q3 2023 Biora Therapeutics Inc Earnings Call TranscriptNov 13, 2023$1.37 (-3.52%)Earnings
- Q2 2023 Biora Therapeutics Inc Earnings Call TranscriptAug 14, 2023$3.17 (-8.38%)Earnings
- Biora Therapeutics Inc Annual Shareholders Meeting TranscriptJun 14, 2023
- Q1 2023 Biora Therapeutics Inc Earnings Call TranscriptMay 15, 2023$3.35 (-10.90%)Earnings
- Q4 2022 Biora Therapeutics Inc Earnings Call TranscriptMar 30, 2023$2.67 (+0.75%)Earnings
- Biora Therapeutics Inc Extraordinary Shareholders Meeting TranscriptDec 19, 2022
- Q3 2022 Biora Therapeutics Inc Earnings Call TranscriptNov 14, 2022$7.03 (+0.75%)Earnings
- Q2 2022 Biora Therapeutics Inc Earnings Call TranscriptAug 15, 2022$26 (+4.00%)Earnings
- Biora Therapeutics Inc Annual Shareholders Meeting TranscriptJun 15, 2022
- Q1 2022 Biora Therapeutics Inc Earnings Call TranscriptMay 10, 2022$19.27 (+1.43%)Earnings
- Q4 2021 Progenity Inc Earnings Call TranscriptMar 28, 2022$40.25 (-4.73%)Earnings
- Q3 2021 Progenity Inc Earnings Call TranscriptNov 10, 2021$88 (+3.23%)Earnings
- Q2 2021 Progenity Inc Earnings Call TranscriptAug 12, 2021$43.5 (-3.87%)Earnings
- Progenity Inc at Raymond James Human Health Innovation Conference (Virtual) TranscriptJun 22, 2021
- Progenity Inc Call to Discuss Strategic Transformation TranscriptJun 02, 2021
- Q1 2021 Progenity Inc Earnings Call TranscriptMay 13, 2021$58.75 (-1.67%)Earnings
- Q4 2020 Progenity Inc Earnings Call TranscriptMar 18, 2021$109.75 (-11.85%)Earnings
- Progenity Inc Preeclampsia Virtual R&D Day TranscriptNov 20, 2020
- Q3 2020 Progenity Inc Earnings Call TranscriptNov 09, 2020$121.75 (-0.20%)Earnings
- Q2 2020 Progenity Inc Earnings Call TranscriptAug 13, 2020$223.75 (-1.97%)Earnings
Progenity Inc Preeclampsia Virtual R&D Day Transcript
Ladies and gentlemen, thank you for standing by and welcome to the Progenity Preeclampsia Virtual R&D Day Conference Call. (Operator Instructions)
I would now like the hand the conference to your speaker today, Dr. Matthew Cooper. Please go ahead, sir.
All right, thank you, Operator. Good morning, everyone, and welcome to Progenity's Preeclampsia R&D Day. Before we get into the program, I must remind you that we'll be making forward-looking statements and for an explanation of the risks and uncertainties associated with those statements, I invite you to review the legal disclaimer shown here on slide two.
So with that out of the way, let's dive in, shall we? I'd like to kick us off by going over the key points we would like for you to take home from the program today.
The focus of R&D Day will be Preecludia, our new brand name for our preeclampsia product. Preecludia addresses a large unmet medical need and aiding physicians in ruling out preeclampsia in mothers
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)